Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.

@article{Nakajima2009ImprovementOR,
  title={Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.},
  author={Shoko Nakajima and Takuya Naruto and Takako Miyamae and Tomoyuki Imagawa and Masaaki Mori and Shigeru Nishimaki and Shunpei Yokota},
  journal={Modern rheumatology},
  year={2009},
  volume={19 1},
  pages={42-6}
}
In this study, we determined serum cartilage oligomeric matrix protein (COMP) levels in systemic juvenile idiopathic arthritis (sJIA) patients during both the active and the remission phases to investigate how the growth cartilage turnover changed under tocilizumab treatment. Specimens were collected from 201 healthy children under 16 years of age with no growth impairment, and paired sera were collected from 11 sJIA patients treated with tocilizumab. Disease activity was assessed from white… CONTINUE READING